Trial Profile
Matched Paired Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Jan 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 25 May 2021 Planned End Date changed from 1 Jun 2023 to 31 Jul 2024.
- 25 May 2021 Planned primary completion date changed from 1 Jun 2022 to 31 Jul 2024.
- 04 Feb 2021 Status changed from recruiting to active, no longer recruiting.